{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:15:35Z","timestamp":1794960935548,"version":"4.9.1"},"reference-count":126,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transplantation of umbilical cord blood (UCB) is an attractive alternative source of hematopoietic stem cells (HSCs). The unique properties of cord blood and its distinct immune tolerance and engraftment kinetics compared to bone marrow (BM) and peripheral blood progenitor cells, permit a wider disparity in human leukocyte antigen levels between a cord blood donor and recipient after an unrelated umbilical cord blood transplant (UCBT). In addition, it is readily available and has a lowered risk of graft-versus-host disease (GvHD), with similar long-term clinical outcomes, compared to BM transplants. However, the relatively low number of cells administered by UCB units, as well as the associated delayed engraftment and immune reconstitution, pose limitations to the wide application of UCBT. Research into several aspects of UCBT has been evaluated, including the ex vivo expansion of cord blood HSCs and the process of fucosylation to enhance engraftment. Additionally, UCB has also been used in the treatment of several neurodegenerative and cardiovascular disorders with varying degrees of success. In this article, we will discuss the biology, clinical indications, and benefits of UCBT in pediatric and adult populations. We will also discuss future directions for the use of cord blood.<\/jats:p>","DOI":"10.1093\/stcltm\/szac086","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T14:26:27Z","timestamp":1676298387000},"page":"55-71","source":"Crossref","is-referenced-by-count":51,"title":["Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1000-1643","authenticated-orcid":false,"given":"Gabriela","family":"Sanchez-Petitto","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplant and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplant and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Daher","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplant and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Rafei","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplant and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplant and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J","family":"Shpall","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplant and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Olson","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplant and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"issue":"2","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2141.2009.07828.x","article-title":"Alternative haematopoietic stem cell sources for transplantation: Place of umbilical cord blood","volume":"147","author":"Smith","year":"2009","journal-title":"Br J Haematol"},{"key":"2023040207310712200_","first-page":"1541","article-title":"Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities","volume-title":"Biol Blood Marrow Transplant","author":"Barker","year":"2010"},{"issue":"4","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/bmt.2012.150","article-title":"Race\/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization","volume":"48","author":"Pidala","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"15561","DOI":"10.12688\/f1000research.11952.1","article-title":"Update on umbilical cord blood transplantation","volume":"6","author":"Ballen","year":"2017","journal-title":"F1000Research"},{"issue":"10","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1182\/blood-2007-06-098020","article-title":"Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies","volume":"112","author":"Kurtzberg","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bbmt.2005.09.016","article-title":"Results of the Cord Blood Transplantation Study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases","volume":"12","author":"Martin","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023040207310712200_","first-page":"2885","article-title":"Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation","author":"Popat","year":"2015"},{"key":"2023040207310712200_","first-page":"437-5","article-title":"Thomas\u2019 hematopoietic cell transplantation.","volume-title":". Thomas\u2019 Hematopoietic Cell Transplantation","author":"Broxmeyer","year":"2019","edition":"5th ed"},{"issue":"5","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.ogx.0000160567.41260.a4","article-title":"Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia: commentary","volume":"60","author":"Champlin","year":"2005","journal-title":"Obstet Gynecol Surv"},{"issue":"11","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1182\/blood.V77.11.2360.2360","article-title":"Developmental hematopoiesis in normal human fetal blood","volume":"77","author":"Forestier","year":"1991","journal-title":"Blood"},{"key":"2023040207310712200_","first-page":"2410","article-title":"Thy-1 expression is linked to functional properties of primitive hematopoietic progenitor cells from human umbilical cord blood","volume-title":"Blood","author":"Mayani","year":"1994"},{"issue":"21","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"9857","DOI":"10.1073\/pnas.91.21.9857","article-title":"Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age","volume":"91","author":"Vaziri","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8677","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(89)92036-9","article-title":"In-utero transplantation of fetal liver haemopoietic stem cells in monkeys","volume":"2","author":"Harrison","year":"1989","journal-title":"Lancet"},{"issue":"10","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/bmt.2009.280","article-title":"History of cord blood transplantation","volume":"44","author":"Gluckman","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood.V83.9.2489.bloodjournal8392489","article-title":"Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice","volume":"83","author":"Vormoor","year":"1994","journal-title":"Blood"},{"issue":"10","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1073\/pnas.86.10.3828","article-title":"Human umbilical cord blood as a potential source of transplantable hematopoietic stem\/progenitor cells","volume":"86","author":"Broxmeyer","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1056\/NEJM198910263211707","article-title":"Hematopoietic reconstitution in a patient with Fanconi\u2019s anemia by means of umbilical-cord blood from an HLA-identical sibling","volume":"321","author":"Gluckman","year":"1989","journal-title":"N Engl J Med"},{"key":"2023040207310712200_","first-page":"795","article-title":"Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft- versus-host disease","volume-title":"Blood","author":"Wagner","year":"1996"},{"issue":"22","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199811263392201","article-title":"Outcomes among 562 recipients of placental-blood transplants from unrelated donors","volume":"339","author":"Rubinstein","year":"1998","journal-title":"N Engl J Med"},{"issue":"6","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1537-2995.2005.04428.x","article-title":"Results of the cord blood transplantation (COBLT) study unrelated donor banking program","volume":"45","author":"Kurtzberg","year":"2005","journal-title":"Transfusion"},{"issue":"2","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbmt.2004.11.020","article-title":"Umbilical cord blood transplantation in adults: results of the prospective cord blood transplantation (COBLT)","volume":"11","author":"Cornetta","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199708073370602","article-title":"Outcome of cord-blood transplantation from related and unrelated donors","volume":"337","author":"Gluckman","year":"1997","journal-title":"N Engl J Med"},{"issue":"11","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00006254-200111000-00012","article-title":"Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors","volume":"56","author":"Laughlin","year":"2001","journal-title":"Obstet Gynecol Surv"},{"issue":"5","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1182\/blood-2002-01-0294","article-title":"Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival","volume":"100","author":"Wagner","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2004-07-2717","article-title":"Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy","volume":"105","author":"Barker","year":"2005","journal-title":"Blood"},{"issue":"18","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1405584","article-title":"One-unit versus two-unit cord-blood transplantation for hematologic cancers","volume":"371","author":"Wagner","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2012-08-449108","article-title":"Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia","volume":"121","author":"Scaradavou","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2010-05-285304","article-title":"Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood","volume":"116","author":"Brunstein","year":"2010","journal-title":"Blood"},{"issue":"19","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-220525","article-title":"Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units","volume":"114","author":"Verneris","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1182\/blood-2010-03-276212","article-title":"An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment","volume":"116","author":"Eldjerou","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood-2002-11-3337","article-title":"Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning","volume":"102","author":"Barker","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbmt.2006.08.041","article-title":"Double unrelated reduced-intensity umbilical cord blood transplantation in adults","volume":"13","author":"Ballen","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2008-07-163238","article-title":"Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors","volume":"113","author":"MacMillan","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jval.2018.03.003","article-title":"On the value of the umbilical cord blood supply.","volume":"21","author":"Strong","year":"2018","journal-title":"Value Heal"},{"issue":"3","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.ogx.0000531866.75606.5a","article-title":"Cord blood banking for potential future transplantation","volume":"73","author":"Shearer","year":"2018","journal-title":"Obstet Gynecol Surv"},{"key":"2023040207310712200_","article-title":"Report to congressional committees National Cord Blood Inventory Practices for increasing availability for transplants and related challenges practices for increasing availability for transplants","author":"States U, Accountability G.","year":"2011"},{"issue":"7","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.bbmt.2019.03.013","article-title":"Comparison of graft acquisition and early direct charges of haploidentical related donor transplantation versus umbilical cord blood transplantation","volume":"25","author":"Kanate","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023040207310712200_","first-page":"1541","article-title":"Umbilical cord blood transplantation without antithymocyte globulin results in similar survival but better quality of life compared with unrelated peripheral blood stem cell transplantation for the treatment of acute leukemia\u2014a retrospective study in China","volume-title":"Biol Blood Marrow Transplant","author":"Tong","year":"2017"},{"issue":"8","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41409-022-01721-7","article-title":"Quality of life following cord blood versus matched sibling donor transplantation: pre-transplantation psychiatric and socioeconomic factors significantly impact outcomes","volume":"57","author":"Brewer","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0033-3182(93)71905-2","article-title":"The transplant evaluation rating scalel: a revision of the psychosocial levels system for evaluating organ transplant candidates","volume":"34","author":"Twillman","year":"1993","journal-title":"Psychosomatics"},{"issue":"8","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/bmt.2014.102","article-title":"Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies","volume":"49","author":"Liu","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"2023040207310712200_","first-page":"924","article-title":"Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR","author":"Dehn","year":"2019"},{"issue":"6","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/tan.12792","article-title":"Impact of HLA in cord blood transplantation outcomes","volume":"87","author":"Ruggeri","year":"2016","journal-title":"HLA"},{"issue":"4","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/beha.2001.0170","article-title":"Best practice & research clinical haematology regular article allogeneic transplantation across major HLA barriers","volume":"14","author":"Henslee-Downey","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"issue":"13","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1744-313X.2011.01040.x","article-title":"Human leucocyte antigen typing: techniques and technology, a critical appraisal","volume":"38","author":"Dunn","year":"2011","journal-title":"Int J Immunogenet"},{"key":"2023040207310712200_","first-page":"1","article-title":"Allele-level HLA matching for umbilical-cord blood transplantation for nonmalignant diseases in children: a retrospective analysis","volume-title":"Lancet Haematol","author":"Brady","year":"2018"},{"key":"2023040207310712200_","first-page":"1843","article-title":"Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies","volume-title":"Blood","author":"Barker","year":"2010"},{"key":"2023040207310712200_","first-page":"882","article-title":"Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies","volume-title":"Biol Blood Marrow Transplant","author":"Barker","year":"2017"},{"key":"2023040207310712200_","first-page":"1362-7","article-title":"Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants.","author":"Page","year":"2008"},{"issue":"19","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1182\/blood-2014-03-566216","article-title":"Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice","volume":"124","author":"Purtill","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.bmt.1705258","article-title":"Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells","volume":"37","author":"Robinson","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1207285","article-title":"Cord-blood engraftment with ex vivo mesenchymal-cell coculture","volume":"367","author":"de Lima","year":"2012","journal-title":"N Engl J Med"},{"key":"2023040207310712200_","first-page":"368","article-title":"Transplantation of ex vivo expanded cord blood","volume-title":"Biol Blood Marrow Transplant","author":"Shpall","year":"2002"},{"issue":"6203","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.1256337","article-title":"Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal","volume":"345","author":"Fares","year":"2014","journal-title":"Science"},{"issue":"2","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1016\/S2352-3026(19)30202-9","article-title":"Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1\u20132 safety and feasibility study","volume":"7","author":"Cohen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1200\/JCO.18.00053","article-title":"Phase I\/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide","volume":"37","author":"Horwitz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.2021011719","article-title":"Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood-2004-02-0650","article-title":"Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow","volume":"104","author":"Xia","year":"2004","journal-title":"Blood"},{"issue":"9","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1470-2045(08)70180-3","article-title":"Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I\/II study.","volume":"9","author":"Frassoni","year":"2008","journal-title":"Lancet Oncol"},{"issue":"5","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41409-018-0335-x","article-title":"Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study","volume":"54","author":"Bonifazi","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1038\/s41409-021-01275-0","article-title":"Intrabone infusion for allogeneic umbilical cord blood transplantation in children","volume":"56","author":"Vairy","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"issue":"3","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-021-03209-4","article-title":"Engineering the next generation of CAR-NK immunotherapies","volume":"114","author":"Biederst\u00e4dt","year":"2021","journal-title":"Int J Hematol"},{"issue":"6","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"2023040207310712200_","first-page":"1899","article-title":"Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume-title":"Am J Cancer Res","author":"Tang","year":"2018"},{"issue":"6","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"issue":"15","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1200\/JCO.2021.39.15_suppl.7541","article-title":"Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapse","volume":"39","author":"Strati","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"issue":"15","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","article-title":"Successful transfer of umbilical cord blood CD34+ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients","volume":"23","author":"Dolstra","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv"},{"issue":"14","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/bloodadvances.2019000201","article-title":"Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients","volume":"3","author":"Abraham","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/blood-2009-03-213256","article-title":"Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes","volume":"114","author":"Hanley","year":"2009","journal-title":"Blood"},{"issue":"285","key":"2023040207310712200_","first-page":"1","article-title":"CMV-Specific T-cells generated from nai\u0308ve T-cells recognize atypical epitopes and may be protective in vivo","volume":"7","author":"Lemon","year":"2019","journal-title":"Physiol Behav"},{"issue":"5","key":"2023040207310712200_","first-page":"397-4","article-title":"Human umbilical cord blood stem cell transplantation for the treatment of chronic spinal cord injury: electrophysiological changes and long-term efficacy","volume":"8","author":"Yao","year":"2013","journal-title":"Neural Regen Res"},{"issue":"2","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jcyt.2012.09.005","article-title":"Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells","volume":"15","author":"Liu","year":"2013","journal-title":"ytotherapy"},{"issue":"1","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12967-014-0253-7","article-title":"Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury","volume":"12","author":"Cheng","year":"2014","journal-title":"J Transl Med"},{"issue":"11","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3727\/096368916X691411","article-title":"Phase I\u2013II clinical trial assessing safety and efficacy of umbilical cord blood mononuclear cell transplant therapy of chronic complete spinal cord injury","volume":"25","author":"Zhu","year":"2016","journal-title":"Cell Transplant"},{"issue":"9","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.4103\/1673-5374.276340","article-title":"Collagen scaffold combined with human umbilical cord-mesenchymal stem cells transplantation for acute complete spinal cord injury","volume":"15","author":"Deng","year":"2020","journal-title":"Neural Regen Res"},{"issue":"1","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcyt.2020.09.012","article-title":"Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1\/2 pilot study","volume":"23","author":"Yang","year":"2021","journal-title":"Cytotherapy"},{"key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"9721","DOI":"10.2147\/IJGM.S326023","article-title":"Study of the diffusion tensor imaging for preclinical therapeutic efficacy of umbilical cord mesenchymal stem cell transplantation in the treatment of spinal cord injury","volume":"14","author":"Zhao","year":"2021","journal-title":"Int J Gen Med"},{"issue":"2","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jcyt.2020.08.008","article-title":"Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study","volume":"23","author":"Albu","year":"2021","journal-title":"Cytotherapy"},{"key":"2023040207310712200_","first-page":"77","article-title":"Infusion of human umbilical cord blood cells ameliorates hind limb dysfunction in experimental spinal cord injury through anti-inflammatory, vasculogenic and neurotrophic mechanisms","volume-title":"Pediatr Neonatol.","author":"Chen","year":"2008"},{"issue":"1","key":"2023040207310712200_","first-page":"1","article-title":"Umbilical cord blood stem cell mediated downregulation of fas improves functional recovery of rats after spinal cord injury","volume":"23","author":"Dasari","year":"2012","journal-title":"Mol Cell Biochem"},{"issue":"20","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1089\/scd.2014.0487","article-title":"GDF-15 secreted from human umbilical cord blood mesenchymal stem cells delivered through the cerebrospinal fluid promotes hippocampal neurogenesis and synaptic activity in an Alzheimer\u2019s disease model","volume":"24","author":"Kim","year":"2015","journal-title":"Stem Cells Dev"},{"issue":"1","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/1567205013666161004151416","article-title":"Human umbilical cord stem cell xenografts improve cognitive decline and reduce the amyloid burden in a mouse model of Alzheimer\u2019s disease","volume":"14","author":"Boutajangout","year":"2016","journal-title":"Curr Alzheimer Res"},{"key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbr.2016.12.021","article-title":"Human umbilical cord mesenchymal stem cells transplantation improves cognitive function in Alzheimer\u2019s disease mice by decreasing oxidative stress and promoting hippocampal neurogenesis","volume":"320","author":"Cui","year":"2017","journal-title":"Behav Brain Res"},{"issue":"2","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.trci.2015.06.007","article-title":"Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer\u2019s disease dementia: a phase 1 clinical trial","volume":"1","author":"Kim","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"2023040207310712200_","first-page":"1","article-title":"Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer\u2019s disease dementia: a phase I clinical trial.","volume":"13","author":"Kim","year":"2021","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"10","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCRESAHA.117.310712","article-title":"Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1\/2 randomized controlled trial (RIMECARD trial [Randomized clinical trial of intravenous infusion umbilical cord mesenchymal","volume":"121","author":"Bartolucci","year":"2017","journal-title":"Circ Res"},{"key":"2023040207310712200_","first-page":"3010","article-title":"Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure","volume-title":"Genet Mol Res","author":"Zhao","year":"2015"},{"key":"2023040207310712200_","first-page":"3328","article-title":"Functional characterization of human umbilical cord-derived mesenchymal stem cells for treatment of systolic heart failure.","author":"Fang","year":"2016"},{"key":"2023040207310712200_","first-page":"172","article-title":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial","volume-title":"Signal Transduct Target Ther","author":"Meng","year":"2020"},{"issue":"1","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-01875-5","article-title":"Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells","volume":"11","author":"Shu","year":"2020","journal-title":"Stem Cell Res Ther"},{"issue":"9","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/sctm.21-0046","article-title":"Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial","volume":"10","author":"Dilogo","year":"2021","journal-title":"Stem Cells Transl Med"},{"issue":"12","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41422-021-00573-y","article-title":"Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms","volume":"31","author":"Zhu","year":"2021","journal-title":"Cell Res"},{"issue":"4","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jinf.2020.05.020","article-title":"Mesenchymal stem cell therapy in severe COVID-19: a retrospective study of short-term treatment efficacy and side effects","volume":"81","author":"Chen","year":"2020","journal-title":"J Infect"},{"key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"0963689721102491","DOI":"10.1177\/09636897211024942","article-title":"The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial","volume":"30","author":"Adas","year":"2021","journal-title":"Cell Transplant"},{"issue":"12","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cpr.12947","article-title":"Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: a pilot study","volume":"53","author":"Feng","year":"2020","journal-title":"Cell Prolif"},{"issue":"1","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-021-02165-4","article-title":"Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series","volume":"12","author":"Hashemian","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/sctm.20-0472","article-title":"Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1\/2a, randomized controlled trial","volume":"10","author":"Lanzoni","year":"2021","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-021-00488-5","article-title":"Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"6","author":"Shi","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"360","DOI":"10.14336\/AD.2020.1218","article-title":"Mesenchymal stem cells for the compassionate treatment of severe acute respiratory distress syndrome due to COVID 19","volume":"12","author":"Iglesias","year":"2021","journal-title":"Aging Dis"},{"key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"e2604","DOI":"10.6061\/clinics\/2021\/e2604","article-title":"Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19","volume":"76","author":"Wei","year":"2021","journal-title":"Clinics"},{"issue":"2(24","key":"2023040207310712200_","first-page":"4504","article-title":"Methods of isolation, expansion, differentiating induction and preservation of human umbilical cord mesenchymal stem cells","volume":"125","author":"JH. LD and C","year":"2012","journal-title":"Chin Med J (Engl)."},{"issue":"9","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/sctm.17-0244","article-title":"Factors influencing the umbilical cord blood stem cell industry: an evolving treatment landscape","volume":"7","author":"Dessels","year":"2018","journal-title":"Stem Cells Transl Med"},{"issue":"10","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/TP.0b013e318288ca4d","article-title":"Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies","volume":"95","author":"Rocha","year":"2013","journal-title":"Transplantation"},{"issue":"25","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1182\/blood-2016-05-715292","article-title":"Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation","volume":"128","author":"Aljitawi","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bmt.1703137","article-title":"A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation","volume":"28","author":"Pecora","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1182\/blood-2001-12-0290","article-title":"Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell system","volume":"101","author":"Jaroscak","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/14653240410004916","article-title":"Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine","volume":"6","author":"Peled","year":"2004","journal-title":"Cytotherapy"},{"issue":"9","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.bmt.1705979","article-title":"Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I\/II clinical trial","volume":"41","author":"de Lima","year":"2008","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/1467-8624.00164","article-title":"Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution","volume":"73","author":"Luthar","year":"2000","journal-title":"Child Dev"},{"issue":"4","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bcmd.2011.08.003","article-title":"In vitro effects of stromal cells expressing different levels of Jagged-1 and Delta-1 on the growth of primitive and intermediate CD34(+) cell subsets from human cord blood","volume":"47","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"2023040207310712200_","first-page":"144","article-title":"Phase I\/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft","volume-title":"Cell Stem Cell","author":"Wagner","year":"2016"},{"issue":"1","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-015-0267-y","article-title":"In vitro and in vivo evaluation of cord blood hematopoietic stem and progenitor cells amplified with glycosaminoglycan mimetic","volume":"7","author":"Faivre","year":"2016","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/sctm.17-0251","article-title":"Ex vivo expansion of CD34+CD90+CD49f+ hematopoietic stem and progenitor cells from non-enriched umbilical cord blood with azole compounds","volume":"7","author":"Bari","year":"2018","journal-title":"Stem Cells Transl Med"},{"key":"2023040207310712200_","first-page":"100","article-title":"Myocardial regeneration strategy using Wharton \u2019 s jelly mesenchymal stem cells as an off-the-shelf \u201c unlimited \u201d therapeutic agent: results from the Acute Myocardial Infarction First-in-Man Study","volume-title":"Postepy Kardiol Interwencyjnej","author":"Musialek","year":"2015"},{"issue":"11","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2174\/1381612821666141126100636","article-title":"Safety and efficacy of intracoronary human umbilical cord-derived mesenchymal stem cell treatment for very old patients with coronary chronic total occlusion","volume":"21","author":"Li","year":"2015","journal-title":"Curr Pharm Des"},{"key":"2023040207310712200_","first-page":"1","article-title":"Intracoronary infusion of Wharton\u2019s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial","volume-title":"BMC Med","author":"Gao","year":"2015"},{"issue":"3","key":"2023040207310712200_","doi-asserted-by":"crossref","first-page":"364","DOI":"10.15283\/ijsc20075","article-title":"Intramyocardial transplantation of umbilical cord mesenchymal stromal cells in chronic ischemic cardiomyopathy: a controlled, randomized clinical trial (HUC-HEART Trial)","volume":"13","author":"Ulus","year":"2020","journal-title":"Int J Stem Cells"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/12\/2\/55\/49725933\/szac086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/12\/2\/55\/49725933\/szac086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T12:36:45Z","timestamp":1701607005000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/12\/2\/55\/7035391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":126,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,13]]},"published-print":{"date-parts":[[2023,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szac086","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2023,2,1]]}}}